Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

Autor: Suzanne Kafaja, Philip J. Clements, Holly Wilhalme, Chi-hong Tseng, Daniel E. Furst, Grace Hyun Kim, Jonathan Goldin, Elizabeth R. Volkmann, Michael D. Roth, Donald P. Tashkin, Dinesh Khanna, Ann Arbor, D. Khanna, Los Angeles, P. J. Clements, D. P. Tashkin, R. Elashoff, J. Goldin, M. Roth, D. Furst, K. Bulpitt, W.-L. J. Chung, S. Viasco, M. Sterz, L. Woolcock, X. Yan, J. Ho, S. Vasunilashorn, I. da Costa, J. R. Seibold, D. J. Riley, J. K. Amorosa, V. M. Hsu, D. A. McCloskey, J. E. Wilson, J. Varga, D. Schraufnagel, A. Wilbur, D. Lapota, S. Arami, P. Cole-Saffold, R. Simms, A. Theodore, P. Clarke, J. Korn, K. Tobin, M. Nuite, R. Silver, M. Bolster, C. Strange, S. Schabel, E. Smith, J. Arnold, K. Caldwell, M. Bonner, R. Wise, F. Wigley, B. White, L. Hummers, M. Bohlman, A. Polito, G. Leatherman, E. Forbes, M. Daniel, V. Steen, C. Read, C. Cooper, S. Wheaton, A. Carey, A. Ortiz, M. Mayes, E. Parsley, S. Oldham, T. Filemon, S. Jordan, M. Perry, null K. Connolly, J. Golden, P. Wolters, R. Webb, J. Davis, C. Antolos, C. Maynetto, B. Fessler, M. Olman, C. Sanders, L. Heck, T. Parkhill, N. Rothfield, M. Metersky, R. Cobb, M. Aberles, F. Ingenito, E. Breen, K. Mubarak, J. L. Granda, J. Silva, Z. Injic, R. Alexander, S. Springmeyer, S. Kirkland, J. Molitor, R. Hinke, A. Mondt, T. Thompson, S. Rounds, M. Weinstein, B. Thompson, H. Paulus, S. Levy, D. Martin, E. Kissin, F. Y. Cheong, G. Marlis, J. Mason-Berry, P. Saffold, M. Rodriguez, L. Guzman, J. Brook, G. Ibrahim, K. Largaespada, C. Fridley, M. Zulmastashvili, A. Manu, S. Moore, F. N. Hant, K. Gibson, M. Morrison, H. Donnelly, C. Marlin, J. Gangar, A. Eller, D. Leong, M. Lalosh, J. Obata, D. Franklin, E. Schiopu, M. Benedict-Blue, V. Leone, J. Shaw, F. Tan, J. Anderson, A. Saulino, P. Carey, M. Esplin, P. Carlson

Publikováno v: American journal of respiratory and critical care medicine. 197(5)

Rationale: FVC percent predicted (FVC%) is the primary outcome measure in clinical trials of systemic sclerosis interstitial lung disease. For interpretation of change in the FVC% over time, it is important to define whether these changes are clinica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85f4196559588eeaa282cfc49e0fb9be
https://pubmed.ncbi.nlm.nih.gov/29186664

Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus

Autor: B H, Hahn, R R, Singh, W K, Wong, B P, Tsao, K, Bulpitt, F M, Ebling

Publikováno v: Arthritis and rheumatism. 44(2)

To test the hypothesis that an artificial peptide, based on an algorithm describing T cell stimulatory sequences from the VH regions of murine IgG antibodies to DNA, is an effective tolerogen in vivo in the (NZB/NZW)F1 (BWF1) mouse model of systemic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6f75b692161c6953dd747e664668177b
https://pubmed.ncbi.nlm.nih.gov/11229475

Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists

Autor: H E, Paulus, B, Ramos, W K, Wong, A, Ahmed, K, Bulpitt, G, Park, M, Sterz, P, Clements

Publikováno v: The Journal of rheumatology. 26(11)

In an additive cohort of patients with early rheumatoid arthritis (RA), to determine the effect of substituting one acute phase reactant for another on the number of patients satisfying the American College of Rheumatology (ACR) 20% preliminary crite

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9718187d32b7abeb190a2b8368c1ab15
https://pubmed.ncbi.nlm.nih.gov/10555885

Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases

Autor: H J, Williams, G S, Alarcón, R, Neuner, V D, Steen, K, Bulpitt, D O, Clegg, C M, Ziminski, M E, Luggen, R P, Polisson, R F, Willkens, C, Yarboro, J, Morgan, M J, Egger, J R, Ward

Publikováno v: The Journal of rheumatology. 25(2)

To review the diagnoses after 5 years in patients who were identified within 12 months of the onset of well established and undifferentiated connective tissue diseases (CTD); to examine death rates and disease remissions in these patients.This incept

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5f2b6df561635694e651b9c054754eca
https://pubmed.ncbi.nlm.nih.gov/9489817

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.